AIMS: Longstanding liver inflammation leads to hepatic regeneration and fibrosis, which subsequently progresses to cirrhosis in some patients with chronic hepatitis B virus (HBV) infection. It remains unclear, however, if the histological severity of chronic hepatitis B (CHB) may determine the development of hepatocellular carcinoma (HCC). The aim of this study was to evaluate the effects of necroinflammation and fibrosis at presentation of CHB on the development of HCC. METHODS: Medical records and radiographs of 796 biopsy-confirmed CHB patients were reviewed retrospectively for a median period of 107 months (6-218) (median age 34 years (18-64), male:female 636:160). Eighty-five per cent (680/796) of patients were treated with antiviral agents such as interferon alpha and/or lamivudine. All the patients were followed at a regular interval of 3-6 months with routine laboratory tests. Abdominal imagings together with serum alpha-fetoprotein were checked every 6-12 months to detect new HCC. Necroinflammation and fibrosis were assessed semiquantitatively. Univariate and multivariate analyses were performed to identify significant risk factors for HCC. RESULTS: HCC developed in 3.4% (27/796) of patients during follow-up. The overall cumulative occurrence rates of HCC were 0.5% and 3.5% at 5 and 10 years, respectively. In multivariate analysis, age over 40 years (p<0.001), advanced fibrosis (p=0.006) and severe lobular activity (p=0.038) at presentation were independent risk factors for the development of HCC. CONCLUSION: Advanced fibrosis and severe lobular activity rather than porto-periportal activity on histology at presentation of CHB are independent predisposing risk factors for the development of HCC.
AIMS: Longstanding liver inflammation leads to hepatic regeneration and fibrosis, which subsequently progresses to cirrhosis in some patients with chronic hepatitis B virus (HBV) infection. It remains unclear, however, if the histological severity of chronic hepatitis B (CHB) may determine the development of hepatocellular carcinoma (HCC). The aim of this study was to evaluate the effects of necroinflammation and fibrosis at presentation of CHB on the development of HCC. METHODS: Medical records and radiographs of 796 biopsy-confirmed CHB patients were reviewed retrospectively for a median period of 107 months (6-218) (median age 34 years (18-64), male:female 636:160). Eighty-five per cent (680/796) of patients were treated with antiviral agents such as interferon alpha and/or lamivudine. All the patients were followed at a regular interval of 3-6 months with routine laboratory tests. Abdominal imagings together with serum alpha-fetoprotein were checked every 6-12 months to detect new HCC. Necroinflammation and fibrosis were assessed semiquantitatively. Univariate and multivariate analyses were performed to identify significant risk factors for HCC. RESULTS: HCC developed in 3.4% (27/796) of patients during follow-up. The overall cumulative occurrence rates of HCC were 0.5% and 3.5% at 5 and 10 years, respectively. In multivariate analysis, age over 40 years (p<0.001), advanced fibrosis (p=0.006) and severe lobular activity (p=0.038) at presentation were independent risk factors for the development of HCC. CONCLUSION: Advanced fibrosis and severe lobular activity rather than porto-periportal activity on histology at presentation of CHB are independent predisposing risk factors for the development of HCC.
Authors: Ji Hae Nahm; Hye Sun Lee; Haeryoung Kim; Sun Young Yim; Ji-Hyun Shin; Jeong Eun Yoo; Sang Hoon Ahn; Jin Sub Choi; Ju-Seog Lee; Young Nyun Park Journal: Liver Int Date: 2021-03-25 Impact factor: 5.828